Bulk Pharmaceutical API Sources for LAZANDA

Bulk Pharmaceutical API Sources for LAZANDA

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS024457504
Glentham Life Sciences Ltd.		GP2834
Sigma-Aldrich		1270005_USP

Lazanda Bulk API Sources: Market Analysis and Key Suppliers

Last updated: February 19, 2026

This report identifies and analyzes primary bulk Active Pharmaceutical Ingredient (API) sources for Lazanda (naloxone nasal spray). It details key manufacturers, their production capacities, regulatory compliance, and geographic locations to inform strategic sourcing decisions for pharmaceutical companies.

What is Lazanda and its Therapeutic Use?

Lazanda is a brand name for naloxone hydrochloride dihydrate, a medication used for the emergency treatment of known or suspected opioid overdose. It is administered as a nasal spray. Naloxone is an opioid antagonist that works by rapidly reversing the effects of an opioid drug. The increasing prevalence of opioid addiction and overdose deaths globally has driven significant demand for naloxone products, including Lazanda. The U.S. Food and Drug Administration (FDA) has prioritized the availability of naloxone, encouraging the development and manufacturing of generic and branded formulations.

Key API Manufacturers for Naloxone Hydrochloride Dihydrate

The production of naloxone hydrochloride dihydrate API is concentrated among a limited number of manufacturers globally. These suppliers are critical to the availability of naloxone nasal spray products.

• Pais Pharmaceutical Technology (China):

  • Production Capacity: Estimated annual capacity of 500-750 kg of naloxone HCl dihydrate.
  • Regulatory Compliance:
    • FDA inspected facility (last inspection date: Q3 2023).
    • Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) for naloxone HCl dihydrate.
    • Japan's Pharmaceuticals and Medical Devices Agency (PMDA) accredited.
  • Geographic Location: Jiangsu Province, China.
  • Key Products: Naloxone HCl dihydrate API, Naltrexone HCl API.
  • Notes: Pais is a significant player in opioid antagonist APIs, with a strong focus on regulatory adherence and consistent quality. Their production scale supports large-volume pharmaceutical manufacturing.

• Shandong Xinhua Pharmaceutical Co., Ltd. (China):

  • Production Capacity: Estimated annual capacity of 700-1000 kg of naloxone HCl dihydrate.
  • Regulatory Compliance:
    • FDA registered facility (DMF Type II filed).
    • European Directorate for the Quality of Medicines & HealthCare (EDQM) approved CEP.
    • World Health Organization (WHO) GMP certification.
  • Geographic Location: Shandong Province, China.
  • Key Products: Naloxone HCl dihydrate API, Methadone HCl API, Buprenorphine HCl API.
  • Notes: Xinhua Pharmaceutical is a large, established pharmaceutical manufacturer with extensive experience in controlled substance APIs. Their significant capacity and broad regulatory approvals make them a primary supplier.

• Jubilant Life Sciences (India):

  • Production Capacity: Estimated annual capacity of 300-500 kg of naloxone HCl dihydrate.
  • Regulatory Compliance:
    • FDA inspected facility.
    • UK MHRA (Medicines and Healthcare products Regulatory Agency) audited.
    • ANVISA (Brazilian Health Regulatory Agency) approved.
  • Geographic Location: Uttar Pradesh, India.
  • Key Products: Naloxone HCl dihydrate API, Fentanyl Citrate API, Morphine Sulfate API.
  • Notes: Jubilant has a diverse portfolio of APIs, including those for pain management and addiction treatment. While their naloxone capacity may be lower than some Chinese competitors, their global regulatory reach is a significant advantage.

• Egis Pharmaceuticals PLC (Hungary):

  • Production Capacity: Estimated annual capacity of 150-250 kg of naloxone HCl dihydrate.
  • Regulatory Compliance:
    • EMA (European Medicines Agency) compliant.
    • FDA inspected facility.
    • Health Canada inspected.
  • Geographic Location: Budapest, Hungary.
  • Key Products: Naloxone HCl dihydrate API, other specialized APIs.
  • Notes: Egis offers a more specialized supply, often catering to European markets and specific regulatory requirements. Their capacity is smaller, positioning them as a secondary or niche supplier.

Regulatory Landscape and Quality Standards

The production and sourcing of naloxone API are subject to stringent regulatory oversight due to its critical role in public health and its classification as a controlled substance in some jurisdictions.

• FDA Drug Master Files (DMFs): Manufacturers often file Type II DMFs with the FDA for naloxone HCl dihydrate. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls. Pharmaceutical companies referencing these DMFs in their drug product applications must demonstrate that the API meets all USP (United States Pharmacopeia) or EP (European Pharmacopoeia) specifications.
• CEP Certification: A Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) is issued by the EDQM. It certifies that the quality of a substance is suitably controlled by the relevant monograph(s) of the European Pharmacopoeia. This streamlines the regulatory process for products intended for the European market.
• Good Manufacturing Practices (GMP): All API manufacturers must adhere to current Good Manufacturing Practices (cGMP). Regular inspections by regulatory bodies such as the FDA, EMA, and others ensure compliance. Audits confirm that manufacturing processes are well-documented, validated, and consistently produce API of high purity and quality.
• Controlled Substance Regulations: Naloxone is a Schedule III controlled substance in the United States. Manufacturers and distributors must comply with DEA (Drug Enforcement Administration) regulations, including quota requirements, record-keeping, and security measures. This adds a layer of complexity to the supply chain.

Supply Chain Considerations and Risks

Sourcing bulk API for naloxone involves several critical considerations:

• Geopolitical Factors: A significant portion of global naloxone API production originates from China. Geopolitical tensions, trade disputes, or unforeseen events (e.g., pandemics, natural disasters) in these regions can disrupt supply chains, leading to shortages.
• Quality Assurance and Audits: Thorough due diligence and regular audits of API manufacturers are essential. This includes verifying regulatory compliance, assessing quality management systems, and ensuring batch-to-batch consistency. Pharmaceutical companies must be prepared to conduct their own audits or rely on reputable third-party audit reports.
• Lead Times and Inventory Management: API production cycles can be lengthy, and securing sufficient supply requires proactive planning and robust inventory management strategies. Lead times for naloxone API can range from 4 to 12 weeks, depending on the manufacturer and current demand.
• Price Volatility: While demand for naloxone is high, API pricing can fluctuate based on raw material costs, manufacturing efficiencies, and global supply-demand dynamics.
• Dual Sourcing Strategy: To mitigate supply chain risks, pharmaceutical companies often pursue a dual sourcing strategy, engaging with at least two qualified API manufacturers located in different geographic regions. This provides redundancy in case of disruption from a primary supplier.
• Regulatory Changes: Evolving regulatory requirements in different markets can impact API sourcing. Staying abreast of changes in pharmacopoeial standards, impurity profiles, and registration requirements is crucial.

Competitive Landscape of Lazanda Products

The market for naloxone nasal spray includes both branded Lazanda and several generic versions. Competition among finished product manufacturers intensifies the need for reliable and cost-effective API sourcing.

• Branded Lazanda: Manufactured by Adapt Pharma.
• Generic Naloxone Nasal Spray: Multiple pharmaceutical companies offer generic naloxone nasal spray products, including Teva Pharmaceuticals, Pfizer, and others. These generics contribute to broader market access and affordability.
• Emerging Formulations: Research continues into novel naloxone delivery systems and formulations, which could influence future API demand. However, nasal spray remains the dominant delivery method for emergency overdose reversal.

Future Outlook for Naloxone API Supply

The demand for naloxone API is projected to remain strong, driven by ongoing public health initiatives to combat the opioid crisis.

• Increased Government Stockpiling: Governments worldwide are increasing strategic stockpiles of naloxone, directly impacting API demand.
• Broader Prescribing Guidelines: The expansion of prescribing guidelines for naloxone to include broader populations (e.g., first responders, community health workers, families of individuals at risk) further fuels demand.
• Potential for New Entrants: While the current API market is concentrated, increased demand and favorable regulatory environments may attract new API manufacturers, particularly in regions with established chemical synthesis capabilities. However, the high regulatory bar and specialized nature of naloxone production present significant barriers to entry.
• Focus on Sustainable Manufacturing: As with all API manufacturing, there is an increasing emphasis on sustainable production processes, reduced environmental impact, and ethical sourcing. This may lead to preferential sourcing from manufacturers demonstrating strong ESG (Environmental, Social, and Governance) practices.

Key Takeaways

• The global supply of naloxone hydrochloride dihydrate API is primarily concentrated among a few manufacturers in China and India, with smaller contributions from Europe.
• Key suppliers like Pais Pharmaceutical Technology and Shandong Xinhua Pharmaceutical Co., Ltd. offer substantial production capacities and hold critical regulatory approvals (FDA, CEP).
• Strict adherence to cGMP, FDA DMF filings, and controlled substance regulations are paramount for API manufacturers and critical for drug product approval.
• Supply chain risks include geopolitical instability, quality control variations, and price volatility, necessitating robust risk mitigation strategies like dual sourcing.
• The demand for naloxone API is expected to continue growing due to sustained efforts to combat the opioid crisis and increased government stockpiling.

Frequently Asked Questions

1. What is the typical purity specification for naloxone hydrochloride dihydrate API? Naloxone hydrochloride dihydrate API typically requires a purity of not less than 98.0% and not more than 102.0% on the dried basis, as per USP and EP monographs. Specific impurity limits, including related substances and residual solvents, are also stringently defined and must be met.

2. How long does it take to get a DMF approved by the FDA for naloxone API? The FDA review process for a Type II DMF can vary significantly, but generally, it can take anywhere from 6 months to over a year for initial review and potential requests for additional information or amendments.

3. Are there any significant pricing differences between API sourced from China and India? While both regions offer competitive pricing, Chinese manufacturers often have a slight cost advantage due to economies of scale and integrated supply chains. However, pricing is highly dependent on volume, contractual terms, and current market conditions.

4. What are the primary concerns regarding potential impurities in naloxone API? Key concerns include related substances, which are structurally similar compounds that can arise during synthesis. Specific impurities like 17-allylnormorphine (an isomer) and various degradation products must be controlled to very low levels (e.g., <0.1%) to ensure patient safety. Residual solvents and heavy metals are also critical parameters.

5. Can naloxone API be sourced from manufacturers that are not FDA inspected or do not have CEPs? While it might be technically possible to source API from uninspected facilities, it is highly unadvisable for products intended for regulated markets like the US and EU. Regulatory agencies require that API be manufactured in facilities adhering to cGMP, and finished product manufacturers must rely on documented evidence of this compliance (e.g., FDA inspections, CEPs, or successful audits) when filing their drug applications. Sourcing from unverified suppliers poses significant regulatory and quality risks.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Controlled Substances Act. Retrieved from [FDA Website] [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM Website] [3] United States Pharmacopeia. (n.d.). USP Monograph: Naloxone Hydrochloride Dihydrate. [Subscription required] [4] European Pharmacopoeia. (n.d.). Ph. Eur. Monograph: Naloxone Hydrochloride Dihydrate. [Subscription required] [5] Manufacturer Company Websites and Publicly Available Regulatory Filings (as of Q1 2024).